The Effect of Hyaluronic Acid and Chondroitin Sulphate-Based Medical Device Combined with Acid Suppression in the Treatment of Atypical Symptoms in Gastroesophageal Reflux Disease

Gaia Pellegatta, Benedetto Mangiavillano, Rossella Semeraro, Francesco Auriemma, Elisa Carlani, Alessandro Fugazza, Edoardo Vespa, Alessandro Repici, Gaia Pellegatta, Benedetto Mangiavillano, Rossella Semeraro, Francesco Auriemma, Elisa Carlani, Alessandro Fugazza, Edoardo Vespa, Alessandro Repici

Abstract

Extraesophageal reflux symptoms are increasingly common in the Western population and their clinical management is still controversial. Although therapy with proton-pump inhibitors (PPIs) represents the gold standard, to date, many patients are refractory to this treatment. The aim of this study was to evaluate, in patients with a recent diagnosis of GERD experiencing extraesophageal symptoms, the efficacy and safety of a 6-week treatment with PPI acid suppression in combination with Gerdoff® (a hyaluronic acid and chondroitin sulphate-based medical device) compared to PPI monotherapy. The trial verified the reduction in symptom frequency and severity by evaluating the proportion of Responders and Non-Responder patients after 6 weeks of treatment, compared to baseline. The effects of Gerdoff® + PPI treatment on extraesophageal symptoms were also evaluated after a 12-week follow up only in Responder patients. The analysis of the change in total Reflux Symptoms Index (RSI) score from baseline to the other time points showed that the extent of the decrease from baseline was higher in the Gerdoff® + PPI group than in the PPI group at any time point. However, the comparison between groups did not show statistically significant differences at any time point. A statistically significant difference, in favor of the Gerdoff® + PPI group, was observed for individual RSI items. Even if the trial showed some limitations, this is the first published study on the efficacy of a medical device containing hyaluronic acid and chondroitin sulphate with antacid in the treatment of extraesophageal reflux symptoms.

Keywords: chondroitin sulphate; extraesophageal reflux symptoms; gastroesophageal reflux disease; hyaluronic acid.

Conflict of interest statement

The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. All authors declare no other competing interest.

Figures

Figure 1
Figure 1
Study diagram. At baseline visit (visit V1), the enrolled patients were randomized with a 1:1 ratio in one of treatment groups: Group 1 (PPI + Gerdoff®) or Group 2 (PPI; control group). After the treatment period (6 weeks), the responders of Group 1 were further randomized with a 1:1 ratio in one of following groups defined according to the treatment: Group Gerdoff® or Group Not-Treated. At week 12 from visit V1 (visit V5), the treatment was interrupted. The assessment of treatment effect maintenance was prolonged for a 6-week follow-up period (visit V6: week 18 from visit V1); PPI, proton pomp inhibitors.
Figure 2
Figure 2
Distribution of responders at week 6 in the two groups. The percentages of responders at Week 6 in the treatment groups (Gerdoff® + omeprazole or omeprazole) were reported (p = 0.0496 in the Chi-squared test).

References

    1. Vakil N., Van Zanten S.V., Kahrilas P., Dent J., Jones R., Global Consensus Group The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am. J. Gastroenterol. 2006;101:1900–1920. doi: 10.1111/j.1572-0241.2006.00630.x.
    1. Wong R.K., Hanson D.G., Waring P.J., Shaw G. ENT manifestations of gastroesophageal reflux. Am. J. Gastroenterol. 2000;95:S15–S22. doi: 10.1016/S0002-9270(00)01074-1.
    1. Dore M.P., Pedroni A., Pes G.M., Maragkoudakis E., Tadeu V., Pirina P., Realdi G., Delitala G., Malaty H.M. Effect of antisecretory therapy on atypical symptoms in gastroesophageal reflux disease. Dig. Dis. Sci. 2007;52:463–468. doi: 10.1007/s10620-006-9573-7.
    1. Pacheco A., Cobeta I., Wagner C. Refractory Chronic Cough: New Perspectives in Diagnosis and Treatment. Arch. Bronconeumol. 2013;49:151–157. doi: 10.1016/j.arbres.2012.09.009.
    1. Altman K.W., Stephens R.M., Lyttle C.S., Weiss K.B. Changing Impact of Gastroesophageal Reflux in Medical and Otolaryngology Practice. Laryngoscope. 2005;115:1145–1153. doi: 10.1097/01.MLG.0000165464.75164.E5.
    1. Fraser A.G. Review article: Gastro-oesophageal reflux and laryngeal symptoms. Aliment. Pharmacol. Ther. 1994;8:265–272. doi: 10.1111/j.1365-2036.1994.tb00287.x.
    1. Yadlapati R., Pandolfino J.E., Lidder A.K., Shabeeb N., Jaiyeola D.-M., Adkins C., Agrawal N., Cooper A., Price C.P.E., Ciolino J.D., et al. Oropharyngeal pH Testing Does Not Predict Response to Proton Pump Inhibitor Therapy in Patients with Laryngeal Symptoms. Am. J. Gastroenterol. 2016;111:1517–1524. doi: 10.1038/ajg.2016.145.
    1. Zerbib F., Bredenoord A.J., Fass R., Kahrilas P.J., Roman S., Savarino E., Sifrim D., Vaezi M., Yadlapati R., Gyawali C. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol. Motil. 2021;33:e14075. doi: 10.1111/nmo.14075.
    1. Yadlapati R., Gyawali C.P., Pandolfino J.E., Chang K., Kahrilas P.J., Katz P.O., Katzka D., Komaduri S., Lipham J., Menard-Katcher P., et al. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin. Gastroenterol. Hepatol. 2022 doi: 10.1016/j.cgh.2022.01.025. S1542-3565(22)00079-9.
    1. Pellegatta G., Spadaccini M., Lamonaca L., Craviotto V., D’Amico F., Ceriotti L., Meloni M., Repici A. Evaluation of Human Esophageal Epithelium Permeability in Presence of Different Formulations Containing Hyaluronic Acid and Chondroitin Sulphate. Med. Devices Évid. Res. 2020;13:57–66. doi: 10.2147/MDER.S234810.
    1. Schindler A., Mozzanica F., Ginocchio D., Peri A., Bottero A., Ottaviani F. Reliability and Clinical Validity of the Italian Reflux Symptom Index. J. Voice. 2010;24:354–358. doi: 10.1016/j.jvoice.2008.08.008.
    1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines for Good Clinical Practice. 1996. [(accessed on 10 March 2022)]. Available online: .
    1. World Medical Association (WMA) Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2013. [(accessed on 10 March 2022)]. Available online:
    1. Wei C. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux. Eur. Arch. Oto-Rhino-Laryngol. 2016;273:3795–3801. doi: 10.1007/s00405-016-4142-y.
    1. O’hara J., Stocken D.D., Watson G.C., Fouweather T., McGlashan J., MacKenzie K., Carding P., Karagama Y., Wood R., Wilson J.A. Use of proton pump inhibitors to treat persistent throat symptoms: Multicentre, double blind, randomised, placebo controlled trial. BMJ. 2021;372:m4903. doi: 10.1136/bmj.m4903.
    1. Wilson J.A., Stocken D.D., Watson G.C., Fouweather T., McGlashan J., MacKenzie K., Carding P., Karagama Y., Harries M., Ball S., et al. Lansoprazole for persistent throat symptoms in secondary care: The TOPPITS RCT. Health Technol. Assess. 2021;25:1–118. doi: 10.3310/hta25030.
    1. Qadeer M.A., Phillips C.O., Lopez A.R., Steward D.L., Noordzij J.P., Wo J.M., Suurna M., Havas T., Howden C.W., Vaezi M.F. Proton Pump Inhibitor Therapy for Suspected GERD-Related Chronic Laryngitis: A Meta-Analysis of Randomized Controlled Trials. Am. J. Gastroenterol. 2006;101:2646–2654. doi: 10.1111/j.1572-0241.2006.00844.x.
    1. Gatta L., Vaira D., Sorrenti G., Zucchini S., Sama C., Vakil N. Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews. Centre for Reviews and Dissemination; York, UK: 2007. Meta-analysis: The efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease.
    1. Spantideas N., Drosou E., Bougea A., AlAbdulwahed R. Proton Pump Inhibitors for the Treatment of Laryngopharyngeal Reflux. A Systematic Review. J. Voice. 2020;34:918–929. doi: 10.1016/j.jvoice.2019.05.005.
    1. Chang A.B., Connor F.L., Petsky H.L., Eastburn M.M., Lewindon P.J., Hall C., Wilson S.J., Katelaris P.H. An objective study of acid reflux and cough in children using an ambulatory pHmetry-cough logger. Arch. Dis. Child. 2011;96:468–472. doi: 10.1136/adc.2009.177733.
    1. Hopkins C., Yousaf U., Pedersen M. Acid reflux treatment for hoarseness. Cochrane Database Syst. Rev. 2006:CD005054. doi: 10.1002/14651858.CD005054.pub2.
    1. Lechien J.R., Saussez S., Schindler A., Karkos P.D., Hamdan A.L., Harmegnies B., De Marrez L.G., Finck C., Journe F., Paesmans M., et al. Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis. Laryngoscope. 2019;129:1174–1187. doi: 10.1002/lary.27591.
    1. Yadlapati R., Kaizer A.M., Sikavi D.R., Greytak M., Cai J.X., Carroll T.L., Gupta S., Wani S., Menard-Katcher P., Wu T.-C., et al. Distinct Clinical Physiologic Phenotypes of Patients with Laryngeal Symptoms Referred for Reflux Evaluation. Clin. Gastroenterol. Hepatol. 2022;20:776–786. doi: 10.1016/j.cgh.2021.05.025.
    1. Sereg-Bahar M., Jerin A., Jansa R., Stabuc B., Hocevar-Boltezar I. Pepsin and bile acids in saliva in patients with laryngopharyngeal reflux—A prospective comparative study. Clin. Otolaryngol. 2015;40:234–239. doi: 10.1111/coa.12358.
    1. Lechien J.R., Saussez S., Karkos P.D. Current Opinion in Otolaryngology and Head and Neck Surgery. Volume 26. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2018. Laryngopharyngeal reflux disease: Clinical presentation, diagnosis and therapeutic challenges in 2018; pp. 392–402.
    1. Wilkie M.D., Fraser H.M., Raja H. Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux. Eur. Arch. Oto-Rhino-Laryngol. 2018;275:2515–2521. doi: 10.1007/s00405-018-5079-0.
    1. Palmieri B., Corbascio D., Capone S., Lodi D. Preliminary clinical experience with a new natural compound in the treatment of oesophagitis and gastritis: Symptomatic effect. Trends Med. 2009;9:219–225.
    1. Palmieri B., Merighi A., Corbascio D., Rottigni V., Fistetto G., Esposito A. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur. Rev. Med. Pharmacol. Sci. 2013;17:3272–3278.
    1. Savarino V., Pace F., Scarpignato C., the Esoxx Study Group Randomised clinical trial: Mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease—Efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment. Pharmacol. Ther. 2017;45:631–642. doi: 10.1111/apt.13914.
    1. Iannitti T., Morales-Medina J.C., Merighi A., Boarino V., Laurino C., Vadalà M., Palmieri B. A hyaluronic acid- and chondroitin sulfate-based medical device improves gastritis pain, discomfort, and endoscopic features. Drug Deliv. Transl. Res. 2018;8:994–999. doi: 10.1007/s13346-018-0531-7.
    1. Boarino V., Raguzzi I., Marocchi M., Merighi A. Symptomatic response to GERDOFF® in patients with gastro-esophageal reflux disease and poor response to alginates: An exploratory, post-market, open-label study. Turk. J. Gastroenterol. 2020;31:466–473. doi: 10.5152/tjg.2020.19327.
    1. Powell J., Cocks H.C. Mucosal changes in laryngopharyngeal reflux-prevalence, sensitivity, specificity and assessment. Laryngoscope. 2012;123:985–991. doi: 10.1002/lary.23693.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit